3-Chloro-N-cyclopropylcathinone

Last updated
3-Chloro-N-cyclopropylcathinone
3-Chloro-N-cyclopropylcathinone.svg
Clinical data
Other names3Cl-CpC; 3′-Chloro-2-(cyclopropylamino)-propanophenone; 2-(N-Cyclopropylamino)-3-chloropropiophenone; PAL-433; PAL433; RTI-6037-39
Drug class Stimulant; Serotonin releasing agent; Serotonin–norepinephrine–dopamine reuptake inhibitor
Identifiers
  • 1-(3-chlorophenyl)-2-(cyclopropylamino)propan-1-one
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
Formula C12H14ClNO
Molar mass 223.70 g·mol−1
3D model (JSmol)
  • CC(C(=O)C1=CC(=CC=C1)Cl)NC2CC2
  • InChI=1S/C12H14ClNO/c1-8(14-11-5-6-11)12(15)9-3-2-4-10(13)7-9/h2-4,7-8,11,14H,5-6H2,1H3
  • Key:YKOZIWZLLJVPPD-UHFFFAOYSA-N

3-Chloro-N-cyclopropylcathinone (3Cl-CpC; code names PAL-433, RTI-6037-39) is a stimulant and hybrid monoamine releasing agent and monoamine reuptake inhibitor of the cathinone family related to bupropion (3-chloro-N-tert-butylcathinone). [1] [2] [3]

Contents

It acts specifically as a dual serotonin releasing agent (SRA) and serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI). [1] [2] [3] Its EC50 Tooltip half-maximal effective concentration for induction of serotonin release is 1,328 nM, whereas its IC50 Tooltip half-maximal inhibitory concentration values for monoamine reuptake inhibition are 265 to 533 nM for dopamine, 2,150 nM for norepinephrine, and 3,180 nM for serotonin. [1] [2] [3] The drug produces psychostimulant-like effects in animals, with a slow onset of action and a long duration of action. [1] [3] The activities of the individual enantiomers of 3Cl-CpC, (–)-3Cl-CpC (PAL-1122) and (+)-3Cl-CpC (PAL-1123), have also been reported. [2]

3Cl-CpC was first described in the scientific literature by 2009. [1] [2] [3] It was being investigated by the National Institute on Drug Abuse (NIDA) as a potential treatment of stimulant dependence, including cocaine dependence specifically. [1] [2] [3]

See also

References

  1. 1 2 3 4 5 6 Carroll FI, Blough BE, Abraham P, Mills AC, Holleman JA, Wolckenhauer SA, Decker AM, Landavazo A, McElroy KT, Navarro HA, Gatch MB, Forster MJ (November 2009). "Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction". J Med Chem. 52 (21): 6768–6781. doi:10.1021/jm901189z. PMID   19821577.
  2. 1 2 3 4 5 6 Blough BE, Landavazo A, Partilla JS, Baumann MH, Decker AM, Page KM, Rothman RB (June 2014). "Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics". ACS Med Chem Lett. 5 (6): 623–627. doi:10.1021/ml500113s. PMC   4060932 . PMID   24944732.
  3. 1 2 3 4 5 6 Carroll FI, Blough BE, Mascarella SW, Navarro HA, Lukas RJ, Damaj MI (2014). "Bupropion and bupropion analogs as treatments for CNS disorders". Adv Pharmacol. 69: 177–216. doi:10.1016/B978-0-12-420118-7.00005-6. PMID   24484978.



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.